These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 20476847)

  • 1. 5-HT(7) receptor modulators: a medicinal chemistry survey of recent patent literature (2004 - 2009).
    Leopoldo M; Lacivita E; Berardi F; Perrone R
    Expert Opin Ther Pat; 2010 Jun; 20(6):739-54. PubMed ID: 20476847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P2X purinergic receptor ligands: recently patented compounds.
    Gunosewoyo H; Kassiou M
    Expert Opin Ther Pat; 2010 May; 20(5):625-46. PubMed ID: 20205618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phospholipase A2 inhibitors as potential therapeutic agents for the treatment of inflammatory diseases.
    Magrioti V; Kokotos G
    Expert Opin Ther Pat; 2010 Jan; 20(1):1-18. PubMed ID: 20021282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-HT(6) receptor modulators: a patent update. Part 2. Diversity in heterocyclic scaffolds.
    Ivachtchenko AV; Ivanenkov YA; Skorenko AV
    Expert Opin Ther Pat; 2012 Oct; 22(10):1123-68. PubMed ID: 22957857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The therapeutic potential of 5-HT1A receptors: a patent review.
    Lacivita E; Di Pilato P; De Giorgio P; Colabufo NA; Berardi F; Perrone R; Leopoldo M
    Expert Opin Ther Pat; 2012 Aug; 22(8):887-902. PubMed ID: 22788968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-hydroxytryptamine subtype 6 receptor modulators: a patent survey.
    Ivachtchenko AV; Ivanenkov YA; Tkachenko SE
    Expert Opin Ther Pat; 2010 Sep; 20(9):1171-96. PubMed ID: 20716023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New-generation 5-HT4 receptor agonists: potential for treatment of gastrointestinal motility disorders.
    Manabe N; Wong BS; Camilleri M
    Expert Opin Investig Drugs; 2010 Jun; 19(6):765-75. PubMed ID: 20408739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-HT2C receptor modulators: a patent survey.
    Lee J; Jung ME; Lee J
    Expert Opin Ther Pat; 2010 Nov; 20(11):1429-55. PubMed ID: 20849206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel GABA(B) receptor positive modulators: a patent survey.
    Froestl W
    Expert Opin Ther Pat; 2010 Aug; 20(8):1007-17. PubMed ID: 20645682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medicinal chemistry strategies to 5-HT(6) receptor ligands as potential cognitive enhancers and antiobesity agents.
    Holenz J; Pauwels PJ; Díaz JL; Mercè R; Codony X; Buschmann H
    Drug Discov Today; 2006 Apr; 11(7-8):283-99. PubMed ID: 16580970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New patented histone deacetylase inhibitors.
    Wang H; Dymock BW
    Expert Opin Ther Pat; 2009 Dec; 19(12):1727-57. PubMed ID: 19939190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation by 5-HT1A receptors of the 5-HT2 receptor-mediated tachykinin-induced contraction of the rat trachea in vitro.
    Germonpré PR; Joos GF; Pauwels RA
    Br J Pharmacol; 1998 Apr; 123(8):1571-8. PubMed ID: 9605563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombin receptors and their antagonists: an update on the patent literature.
    Cirino G; Severino B
    Expert Opin Ther Pat; 2010 Jul; 20(7):875-84. PubMed ID: 20450349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orexin receptor antagonists: a review of promising compounds patented since 2006.
    Coleman PJ; Renger JJ
    Expert Opin Ther Pat; 2010 Mar; 20(3):307-24. PubMed ID: 20180618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in the development of melatonin MT(1) and MT(2) receptor agonists.
    Mor M; Rivara S; Pala D; Bedini A; Spadoni G; Tarzia G
    Expert Opin Ther Pat; 2010 Aug; 20(8):1059-77. PubMed ID: 20533893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands.
    Holenz J; Mercè R; Díaz JL; Guitart X; Codony X; Dordal A; Romero G; Torrens A; Mas J; Andaluz B; Hernández S; Monroy X; Sánchez E; Hernández E; Pérez R; Cubí R; Sanfeliu O; Buschmann H
    J Med Chem; 2005 Mar; 48(6):1781-95. PubMed ID: 15771424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes.
    Newman-Tancredi A; Cussac D; Quentric Y; Touzard M; Verrièle L; Carpentier N; Millan MJ
    J Pharmacol Exp Ther; 2002 Nov; 303(2):815-22. PubMed ID: 12388668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent patents in the discovery of small molecule inhibitors of JAK3.
    Wilson LJ
    Expert Opin Ther Pat; 2010 May; 20(5):609-23. PubMed ID: 20402545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel 2-aminotetralin and 3-aminochroman derivatives as selective serotonin 5-HT7 receptor agonists and antagonists.
    Holmberg P; Sohn D; Leideborg R; Caldirola P; Zlatoidsky P; Hanson S; Mohell N; Rosqvist S; Nordvall G; Johansson AM; Johansson R
    J Med Chem; 2004 Jul; 47(16):3927-30. PubMed ID: 15267230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective and divergent regulation of cortical 5-HT(2A) receptors in rabbit.
    Aloyo VJ; Dave KD; Rahman T; Harvey JA
    J Pharmacol Exp Ther; 2001 Dec; 299(3):1066-72. PubMed ID: 11714896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.